Interestingly, neither of the 2 MNK1/2 inhibitors tested (SLV-2436 and eFT508) exhibited notable activity in inhibiting MAPK4-induced PDK1 protein expression or tumor cell growth (S3 Fig). Here, MAPK4 is linked to neoplasm.